This nomogram model incorporating clinical factors (age, WHO grade), treatment (radiotherapy, chemotherapy), and tumor markers (ATRX, IDH1, Ki-67) has a good predictive efficacy and may serve as a practical and effective alternative to molecular testing for prediction of survival in adult patients with primary glioma. This evidence concerns the gene IDH1 and neoplasm.